Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
J M Smith sale of smith Technologies to Francisco Partners
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…
Aetna receives DOJ approval of $77 billion acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk Successfully Represents Aetna in Patent Infringement Suit
Davis Polk represents Aetna Inc. and its subsidiaries ActiveHealth Management, Inc. and Medicity, Inc. in a patent infringement suit brought by HealthTrio, LLC. HealthTrio filed the lawsuit…
Davis Polk Wins Summary Judgment of Non-Infringement in Patent Litigation on Behalf of Transcend Medical, Inc.
Davis Polk represents Transcend Medical, Inc., an innovator in the field of Micro-Invasive Glaucoma Surgery, in a patent suit against Glaukos Corporation. Transcend has recently completed a…
Bio-Reference Laboratories $1.47 billion acquisition by OPKO Health
Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…
Warner Chilcott $8.5 billion acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in a stock-for-stock transaction. The transaction is expected to…
HHS-OIG Drops Potential Action Against Howard Solomon
On August 5, 2011, the Office of Inspector General for the Department of Health and Human Services dropped a potential action against Davis Polk client Howard Solomon, the President,…